News | 12.12.19
Medicure Completes Enrollment in FABOLUS-FASTER Trial of Aggrastat in Patients Undergoing PCI
December 12, 2019—Medicure Inc. announced the completion of the FABOLUS-FASTER phase 4 trial of Aggrastat (tirofiban hydrochloride) injection versus Kengreal (cangrelor; The Medicines Company) in patients undergoing percutaneous coronary intervention (PCI).
News | 12.05.19
FDA Approves Enoxaparin Sodium Injection in the United States
December 5, 2019—Meitheal Pharmaceuticals, a generic injectable pharmaceuticals company based in Chicago, Illinois, announced that the FDA has approved the company's enoxaparin sodium injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd., its majority shareholder.
News | 11.19.19
ISCHEMIA Provides Clarity on Invasive Strategies Versus Medical Therapy to Manage Higher-Risk Patients With Stable Ischemic Heart Disease
November 16, 2019—At the American Heart Association (AHA) scientific sessions 2019, held November 16–18 in Philadelphia, Pennsylvania, Judith S. Hochman, MD, presented findings from the ISCHEMIA trial, which sought to determine the best management strategy for higher-risk patients with stable ischemic heart disease and moderate to severe ischemia on stress testing. John A. Spertus, MD, then presented the quality-of-life (QOL) findings from the ISCHEMIA trial.
News | 10.21.19
FDA Approves AstraZeneca's Farxiga for Patients With Type 2 Diabetes
October 21, 2019—AstraZeneca announced that the FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
News | 10.17.19
NICE Publishes Guidance on Rivaroxaban for Preventing Atherothrombotic Events in Patients With CAD or PAD
October 17, 2019—The United Kingdom’s National Institute for Health and Care Excellence (NICE) has published its technology appraisal guidance (TA607) on evidence-based recommendations on rivaroxaban (Xarelto; Bayer AG, marketed in the United States by the Janssen Pharmaceutical Companies of Johnson & Johnson) for preventing atherothrombotic events in adults with coronary artery disease (CAD) or peripheral artery disease (PAD).
News | 10.17.19
Ticagrelor Monotherapy Shows Promise for Patients Undergoing Multivessel PCI in GLOBAL LEADERS Study
October 17, 2019—Data from the GLOBAL LEADERS study suggest that long-term ticagrelor monotherapy after 1-month dual antiplatelet therapy (DAPT) can favorably balance ischemic and bleeding risks in patients undergoing multivessel percutaneous coronary intervention (PCI).
News | 10.15.19
Study Evaluates Preprocedural Anticoagulation for Patients With STEMI Undergoing Primary PCI
October 15, 2019—Online in Catheterization and Cardiovascular Interventions, Warren J. Cantor, MD, et al published findings from an evaluation of upstream anticoagulation for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The investigators sought to assess the relationship between preprocedural anticoagulation use and clinical and angiographic outcomes.
News | 10.14.19
FDA Approves Xarelto for VTE Prevention in Acutely Ill Medical Patients
October 14, 2019—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE) in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
News | 09.27.19
TWILIGHT Study Supports Ticagrelor Monotherapy at 3 Months After PCI and DAPT
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the TWILIGHT study were presented by investigator Roxana Mehran, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.27.19
Onyx ONE Study Evaluates 1-Month DAPT in High-Bleeding Risk Patients
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the Onyx One study were presented by Stephan Windecker, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.26.19
EVOLVE Short DAPT Study Shows Low Rate of Adverse Events in High-Bleeding Risk Patients
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the EVOLVE Short DAPT study were presented by lead investigator Ajay J. Kirtane, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.09.19
Recardio Begins Phase 2 Trial of Dutogliptin in Early Recovery Postmyocardial Infarction
September 9, 2019—Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its phase 2 study of dutogliptin in combination with filgrastim in early recovery postmyocardial infarction is now enrolling and recruiting in multiple European and United States centers.
News | 08.27.19
Study Published on Anticoagulation After Surgical or Transcatheter Aortic Valve Replacement
August 27, 2019—Findings from a study aimed to assess the impact of anticoagulation after bioprosthetic aortic valve replacement (AVR)—either surgical (SAVR) or transcatheter (TAVR)—on valve hemodynamics and clinical outcomes were published by Tarun Chakravarty, MD, et al in Journal of the American College of Cardiology (JACC) (2019;74:1190–1200).
News | 08.20.19
AstraZeneca's Farxiga Meets Primary Endpoint in DAPA-HF Trial
August 20, 2019—AstraZeneca announced the results from its landmark phase 3 DAPA-HF trial, showing that the company's Farxiga (dapagliflozin, a sodium-glucose cotransporter 2 [SGLT2] inhibitor) met the primary composite endpoint with a statistically significant and clinically meaningful reduction of cardiovascular death or worsening heart failure (defined as hospitalization or urgent heart failure visit) compared with placebo.
News | 07.30.19
Alvimedica Receives European Approval for 1-Month DAPT After Implantation of Cre8 and Cre8 Evo DES
July 30, 2019—Alvimedica announced European regulatory approval for 1-month duration of dual antiplatelet therapy (DAPT), when clinically indicated, after implantation of the company's Cre8 and the Cre8 Evo drug-eluting stents (DESs).
News | 07.22.19
Meta-Analysis Shows Midterm Mortality Benefit of Statin Therapy After TAVR
July 22, 2019—A meta-analysis of available studies was performed to determine whether statin (hydroxymethylglutaryl-CoA reductase inhibitor) therapy is associated with better midterm survival after transcatheter aortic valve replacement (TAVR).